| Literature DB >> 28484714 |
Gabriela Hernández-Molina1, José Manuel Rodríguez-Pérez2, Javier Fernández-Torres3,4, Guadalupe Lima1, Nonanzit Pérez-Hernández2, Alberto López-Reyes3, Gabriela Angélica Martínez-Nava3.
Abstract
Objective. To evaluate the allele and genotype frequencies of polymorphic sites of HIF1A and ANKA genes in primary Sjögren's syndrome (pSS). Methods. We included 110 patients with pSS and 141 ethnically matched healthy controls. Three HIF1A gene polymorphisms (Pro582Ser, Ala588Thr, and C191T) and two AKNA gene polymorphisms (-1372C>A and Pro624Leu) were genotyped using TaqMan probes in a Real-Time PCR instrument. Associations between pSS and genotypes, alleles, and inheritance models of the SNPs of interest were evaluated by logistic regression adjusted by age and gender. Results. The C/T genotype and the T allele of the HIF1A Pro582Ser polymorphism protected against pSS (OR = 0.22; 95% CI = 0.09-0.52; P < 0.01; OR = 0.26; 95% CI = 0.12-0.58; P < 0.01, resp.), whereas under a recessive model adjusted by age and gender, the AKNA -1372C>A polymorphism A/A genotype was associated with an increased risk of pSS (OR = 2.60; 95% CI = 1.11-6.12; P = 0.03). Conclusions. We identified HIF1A Pro582Ser T allele and C/T genotype as well as AKNA -1372C>A polymorphism A/A genotype as genetic factors associated with pSS. Further studies in other populations are needed to validate our findings and research is warranted in order to shed some light on their functional implications across biological pathways in this disease.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28484714 PMCID: PMC5397622 DOI: 10.1155/2017/5845849
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Clinical and serological characteristics of PSS patients.
| Variable | Primary Sjögren's syndrome ( |
|---|---|
| Median age in years (interquartile range) | 55 (17) |
| Female, | 105 (95.45) |
| Median disease duration in years (interquartile range) | 7.8 (10) |
| Ocular symptoms, | 90 (90.9) |
| Oral symptoms, | 103 (93.6) |
| Parotid enlargement, | 60 (54.6) |
| Positive Schirmer-I test, | 96 (87.3) |
| Impaired nonstimulated whole salivary flow, | 96/103 (93.2) |
| Positive fluorescein staining, | 53/80 (66.2) |
| Positive anti-Ro/SSA antibodies, | 91 (82.7) |
| Positive anti-La/SSB antibodies, | 53 (48.18) |
| Skin vasculitis, | 2 (1.8) |
| Neurological involvement, | 12 (10.9) |
| Raynaud's phenomenon | 11 (10) |
| Nonerosive arthritis, | 23 (20.9) |
Genotype and allele frequency by study group of HIF1A and AKNA polymorphisms.
| Polymorphism | Frequency |
| ||
|---|---|---|---|---|
| Total study population ( | Controls ( | Primary Sjögren's syndrome ( | ||
|
| ||||
| C/C | 188 (78.0) | 94 (69.6) | 94 (88.7) | <0.01 |
| C/T | 53 (22.0) | 41 (30.4) | 12 (11.3) | |
| T/T | 0 | 0 | 0 | |
| Alleles | ||||
| C | 429 (89.0) | 229 (84.8) | 200 (94.3) | <0.01 |
| T | 53 (11.0) | 41 (15.2) | 12 (5.70) | |
| HWEa | 0.09 | 0.04 | 0.99 | |
|
| ||||
| G/G | 198 (99.5) | 90 (98.9) | 108 (100.0) | 0.46 |
| G/A | 1 (0.5) | 1 (1.10) | 0 | |
| A/A | 0 | 0 | 0 | |
| Alleles | ||||
| G | 397 (99.8) | 181 (99.4) | 216 (100.0) | 0.46 |
| A | 1 (0.25) | 1 (0.60) | 0 | |
| HWE | 0.99 | 0.99 | — | |
|
| ||||
| T/T | 190 (83.0) | 96 (80.7) | 94 (85.4) | 0.38 |
| T/C | 39 (17.0) | 23 (19.3) | 16 (14.6) | |
| C/C | 0 | 0 | 0 | |
| Alleles | ||||
| T | 419 (91.5) | 215 (90.3) | 204 (92.7) | 0.40 |
| C | 39 (8.52) | 23 (9.7) | 16 (7.27) | |
| HWE | 0.38 | 0.60 | 0.99 | |
|
| ||||
| C/C | 72 (29.2) | 41 (29.1) | 31 (29.2) | 0.11 |
| C/A | 137 (55.5) | 84 (59.6) | 53 (50.0) | |
| A/A | 38 (15.4) | 16 (11.3) | 22 (20.8) | |
| Inheritance models | ||||
| C/A + A/A | 175 (70.85) | 100 (70.9) | 75 (70.8) | 0.54 |
| A/Ab | 38 (15.4) | 16 (11.3) | 22 (20.8) | 0.03 |
| Alleles | ||||
| C | 281 (56.9) | 166 (58.9) | 115 (54.2) | 0.18 |
| A | 213 (43.1) | 116 (41.1) | 97 (45.8) | |
| HWE | 0.05 | 0.01 | 0.99 | |
|
| ||||
| G/G | 69 (28.1) | 39 (28.1) | 30 (28.3) | 0.56 |
| G/A | 132 (53.9) | 78 (56.1) | 54 (50.9) | |
| A/A | 44 (18.0) | 22 (20.8) | 22 (20.8) | |
| Inheritance models | ||||
| G/A + A/A | 176 (71.8) | 100 (71.9) | 76 (71.7) | 0.54 |
| A/Ab | 44 (18.0) | 22 (20.8) | 22 (20.8) | 0.20 |
| Alleles | ||||
| G | 270 (55.1) | 156 (56.1) | 114 (53.8) | 0.34 |
| A | 220 (44.9) | 122 (43.9) | 98 (46.2) | |
| HWE | 0.20 | 0.12 | 0.85 | |
aHWE: Hardy Weinberg Equilibrium.
bRecessive inheritance model; the reference group is formed by C/A and C/C genotype carriers or G/A and G/G genotype carriers for each AKNA polymorphism, respectively.
cFisher's exact test P value.
Odds ratio for primary Sjögren's syndrome by polymorphisms genotypes, alleles, and inheritance models.
| Polymorphism |
| ORa (95% CI) |
|
|---|---|---|---|
|
| |||
| C/C | 94/94 | 1.00 | |
| C/T | 41/12 | 0.22 (0.09–0.52)c | <0.01 |
| T/T | 0/0 | — | — |
| Alleles | |||
| C | 229/200 | 1.00 | |
| T | 41/12 | 0.26 (0.12–0.58)c | <0.01 |
|
| |||
| T/T | 96/94 | 1.00 | |
| T/C | 23/16 | 0.43 (0.18–1.04) | 0.06 |
| C/C | 0/0 | — | — |
| Alleles | |||
| T | 215/204 | 1.00 | |
| C | 23/16 | 0.47 (0.21–1.07) | 0.07 |
|
| |||
| C/C | 41/31 | 1.00 | |
| C/A | 84/53 | 0.64 (0.31–1.32) | 0.23 |
| A/A | 16/22 | 1.94 (0.73–5.15) | 0.19 |
| Inheritance models | |||
| C/A + A/A | 100/75 | 0.82 (0.41–1.64) | 0.58 |
| A/Ab | 16/22 | 2.60 (1.11–6.12)c | 0.03 |
| Alleles | |||
| C | 166/115 | 1.00 | |
| A | 116/97 | 1.20 (0.78–1.86) | 0.42 |
|
| |||
| G/G | 39/30 | 1.00 | |
| G/A | 78/54 | 0.76 (0.37–1.58) | 0.46 |
| A/A | 22/22 | 1.56 (0.62–3.96) | 0.35 |
| Inheritance models | |||
| G/A + A/A | 100/76 | 0.92 (0.46–1.83) | 0.80 |
| A/Ab | 22/22 | 1.88 (0.85–4.16) | 0.12 |
| Alleles | |||
| G | 156/114 | 1.00 | |
| A | 122/98 | 1.17 (0.75–1.81) | 0.48 |
aOdds ratio adjusted by age and gender.
bRecessive inheritance model; the reference group is formed by C/A and C/C genotype carriers or G/A and G/G genotype carriers for each AKNA polymorphism, respectively.
cOdds ratio statistically significant after bootstrap resampling (100 repetitions).